A functional TIGIT-associated transcriptional program identifies circulating tumor-reactive CD8⁺ T cells in melanoma patients
Accessing tumor-reactive CD8⁺ T cells in patient blood is essential for non-invasive monitoring of systemic T cell responses and guiding personalized therapies. However, precise functional, molecular, and phenotypic characterization of these cells remains challenging. Here, we identify TIGIT as a functionally validated surrogate marker of tumor-reactive CD8⁺ T cells and define its associated transcriptional program to characterize circulating tumor-reactive CD8⁺ T cells in melanoma patients. We demonstrate that blood TIGIT⁺ CD8⁺ T cells mount robust cytotoxic responses against autologous tumor cells across multiple melanoma patient models, irrespective of PD-1 co-expression. At the clonotype level, TIGIT broadened detection of the circulating tumor-reactive repertoire beyond PD-1 while retaining high specificity. Moreover, circulating TIGIT⁺ CD8⁺ T cell population was closely associated with the intratumoral T cell repertoire and exhibited hallmarks of antigen experience, including effector memory differentiation, a hypomethylated DNA landscape, and increased clonal expansion. Longitudinal profiling of blood samples from melanoma patients undergoing immune checkpoint inhibition revealed an increased frequency of TIGIT⁺ CD8⁺ T cells in clinical responders. Finally, leveraging paired single-cell transcriptomic and TCR data from patient models with identified tumor-reactive clones, we show that the TIGIT-associated transcriptional program enables robust detection of circulating tumor-reactive CD8⁺ T cells. Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.
Authors
- Andreas Heinold (ORCID: https://orcid.org/0000-0002-6996-5156)
- Fang Zhao (ORCID: https://orcid.org/0000-0002-2746-9242)
- Alicia Brüggemann (ORCID: https://orcid.org/0009-0003-8011-5050)
- Inga Möller (ORCID: https://orcid.org/0000-0003-0607-971X)
- Christoph Plass (ORCID: https://orcid.org/0000-0003-2554-3952)
- Maria Llamazares Prada (ORCID: https://orcid.org/0000-0001-6559-9374)
- Alexander Roesch (ORCID: https://orcid.org/0000-0002-0773-6067)
- Korbinian Nepomuk Kropp (ORCID: https://orcid.org/0000-0001-8104-7166)
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
- Florian Rambow (ORCID: https://orcid.org/0000-0002-9727-8986)
- Steffen Hennig (ORCID: https://orcid.org/0009-0005-0986-2760)
- Annette Paschen (ORCID: https://orcid.org/0000-0003-1651-1262)
- Antje Sucker (ORCID: https://orcid.org/0000-0002-2753-9626)
- Volker Lennerz (ORCID: https://orcid.org/0000-0002-9551-907X)
- Anne Zaremba (ORCID: https://orcid.org/0000-0002-6932-0489)
- Yichao Hua (ORCID: https://orcid.org/0000-0002-1695-172X)
- Fatemeh Ghorbani (ORCID: https://orcid.org/0009-0009-3432-6408)
- Katherine A. Kelly (ORCID: https://orcid.org/0009-0003-6043-4927)
- Sabrina Kwapik (ORCID: https://orcid.org/0009-0005-9704-7247)
- Eileen Majewski (ORCID: https://orcid.org/0009-0008-4720-1447)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- German Cancer Research Center (DE)
- Essen University Hospital (DE)
- Gauss Centre for Supercomputing (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Cancer Immunology Research
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1158/2326-6066.cir-26-0327
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Melanoma Research Alliance
- Boettcher Foundation
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe